Insilico Medicine, a biotech startup sponsored by Fosun Group and Warburg Pincus, has initiated one of the first mid-stage human studies of an artificial intelligence-discovered and created medicine. INS018_055 is the first AI-discovered and AI-designed medicine to enter a phase 2 clinical trial in China. Insilico is one of a new wave of biotechs that have raised billions of dollars to build artificial intelligence technologies that will revolutionize medication development. The business uses artificial intelligence tools to pick 12 pre-clinical medication candidates, three of which have moved to clinical trials. According to Zhavoronkov, depending on the uniqueness and complexity of the target, Insilico’s AI might save two to four years in pre-clinical discovery.
However, it did not save much time in clinical development but increased the likelihood of success due to enhanced chemistry and target selection. Insilico also utilized AI to identify patients who would be more likely to react to the medication. However, there is no assurance that AI-discovered treatments or platforms will be effective, and some skeptics believe the technology’s promise has been overstated. Insilico completed phase 1 studies on INS018_055 in New Zealand and China, and the findings were encouraging enough to warrant a phase 2 study. The mid-stage trial will enroll 60 persons with IPF in China and the United States to evaluate the drug’s safety, tolerability, and preliminary effectiveness.
